Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from OS Therapies Incorporated ( (OSTX) ) is now available.
On October 21, 2025, OS Therapies Incorporated held its annual meeting where stockholders approved several key proposals. These included the election of six directors, an amendment to increase the company’s authorized shares, and a shareholder rights agreement. The meeting also saw the approval of an incentive compensation plan amendment and the ratification of MaloneBailey, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. These decisions reflect strategic moves to enhance the company’s operational capabilities and shareholder value.
The most recent analyst rating on (OSTX) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on OS Therapies Incorporated stock, see the OSTX Stock Forecast page.
Spark’s Take on OSTX Stock
According to Spark, TipRanks’ AI Analyst, OSTX is a Underperform.
OS Therapies Incorporated faces significant financial difficulties, marked by increasing net losses, negative cash flows, and reliance on external financing. The technical analysis indicates bearish momentum with the stock trading below its moving averages. Valuation is challenging with no earnings to support a P/E ratio or dividend yield. These factors contribute to a low overall stock score, reflecting the company’s financial instability and negative market sentiment.
To see Spark’s full report on OSTX stock, click here.
More about OS Therapies Incorporated
Average Trading Volume: 504,091
Technical Sentiment Signal: Strong Sell
Current Market Cap: $61.36M
Learn more about OSTX stock on TipRanks’ Stock Analysis page.